Hepatitis C treatment highlights from the 2011 American association for the study of liver disease meeting

Clinical Infectious Diseases

Volumn 55, Issue 3, 2012, Pages 418-425

  Cooper, Curtis ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACH 1625; ANTIVIRUS AGENT; ASUNAPREVIR; BI 207127; BOCEPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; GSK 2336805; IDX 08189; MERICITABINE; MK 4882; MK 5172; N (2' DEOXY 2' FLUORO 2' METHYL P PHENYL 5' URIDYLYL)ALANINE ISOPROPYL ESTER; NARLAPREVIR; PEGINTERFERON; PPI 461; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; TMC 647055; UNCLASSIFIED DRUG; VANIPREVIR; VX 222;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEDICAL SOCIETY; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; PROTEASE INHIBITORS; RIBAVIRIN;

EID: 84863917117     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis375     Document Type: Article

References (63)

1. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-17.
2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
3. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
4. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
5. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-44.
6. Craxi A, Pawlotskly JM, Wedemeyer H, et al. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55:245-64.
7. Bacon BR, Bruno S, Schiff ER, et al. Predictors of sustained virologic response (SVR) among poor interferon (IFN) responders when boceprevir (BOC) is added to peginterferon alfa-2B/ribavirin (PR; abstract 33). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco: Hepatology, 2011:376A.
8. Vierling JM, Flamm SL, Gordon SC, et al. Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: The PROVIDE study (abstract 931). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco: Hepatology, 2011:796A-7A.
9. Sherman KE, Rockstroh JK, Dieterich DT, et al. Telaprevir combination with peginterferon alfa-2A/ribavirin in HCV/HIV co-infected patients: 24-week treatment interim analysis (abstract LB-8). The Liver Meeting (2011)-62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:1431A.
10. Sulkowski MS, Asselah T, Ferenci P, et al. Treatment with the second generation HCV protease inhibitor BI201335 results in high and consistent SVR rates: results from SILEN-C1 in treatment naive patients across different baseline factors (abstract 226). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:473A.
11. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial (abstract 1369). The International Liver Congress (2011) 46th Annual Meeting of the European Association for the Study of the Liver. Vol. 54. Berlin, Germany: Journal of Hepatology, 2011:S542-S3.
12. Fried MW, Buti M, Dore GJ, et al. TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR phase IIB study (abstract LB-5). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:1429A.
13. Terrault N, Cooper C, Balart LA, et al. High sustained virologic resonse (SVR24) rates with response-guided danoprevir (DNV; RG7227) plus PEGIFN α-2A (40KD) and ribavirin (P/R) in treatment-naive HCV genotype 1 (G1) patients: results from the Atlas study (abstract 79). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:398A.
14. Vierling JM, Poordad F, Lawitz E, et al. Once daily narlaprevir (NVR; SCH 900518) and ritonavir (RTV) in combination with peginterferon alfa-2B/ribavirin (PR) for 12 weeks plus 12 weeks PR in treatmentnaive patients with HCV genotype 1 (G1): SVR results from NEXT-1, a phase 2 study (abstract LB-17). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:1437A-8A.
15. Hezode C, Hirschfield GM, Ghesquiere W, et al. BMS-790052, A NS5A replication complex inhibitor, combined with peginterferon alfa-2A and ribivirin in treatment-naive HCV genotype 1 or 4 patients: phase 2B AI444010 study interim week 12 results (abstract 227). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:474A-5A.
16. Izumi N, Asahina Y, Yokosuka O, et al. Combination therapy of treatment-naive and nonresponder patients with HCV genotype 1 infection with BMS-790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa-2A and ribavirin (abstract LB-20). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:1439A-40A.
17. Suzuki F, Chayama K, Kawakami Y, et al. BMS-790052, an NS5A replication complex inhibitor, in combination with peginterferon alpha-2B and ribavirin in Japanese treatment-naive and nonresponder patients with chronic HCV genotype 1 infection (abstract LB-22). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:1441A.
18. Lawitz E, Lalezari JP, Hassanein T, et al. Once-daily PSI-7977 plus PEG/RBV in treatment naive patients with HCV GT1: robust end of treatment response rates are sustained post-treatment (abstract 225). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:472A.
19. Poordad F, Lawitz E, Gordon SC, et al. Concomitant medication use in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy (abstract 937). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:799A-800A.
20. Lok AS, Gardiner D, Lawitz E, et al. Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders (abstract 1356). The International Liver Congress (2011) 46th Annual Meeting of the European Association for the Study of the Liver. Vol. 54. Berlin, Germany: Journal of Hepatology, 2011:S536.
21. Nelson DR, Gane EJ, Jacobson IM, et al. VX-222/telaprevir in combination with peginterferon-alfa-2A and ribavirin in treatment naive genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 intermin analysis (abstract LB-14). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:1435A.
22. Di Bisceglie AM, Nelson DR, Gane E, et al. VX-222 with TVR alone or in combination with pegInterferon alfa-2A and ribavirin in treatment-naïve patients with chronic hepatitis C: ZENITH study interim results (abstract 1363). The International Liver Congress (2011) 46th Annual Meeting of the European Association for the Study of the Liver. Vol. 54. Berlin, Germany: Journal of Hepatology, 2011:S540.
23. Lalezari JP, Agarwal K, Dusheiko G, et al. Dose-ranging trial of PPI-461, a potent new pan-genotypic HCV NS5A inhibitor, in patients with HCV genotype-1 infection (abstract 82). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:400A.
24. Spreen W, Wilfret DA, Bechtel J, et al. GSK2336805 HCV NS5A inhibitor demonstrates potent antiviral activity in chronic genotype 1 infections; Results from a first time in human (FTIH) single and repeat dose study (abstract 83). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:400A-1A.
25. Chayama K, Takahashi S, Kawakami Y, et al. Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1B-infected null responders (abstract LB-4). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:1428A.
26. Zeuzem S, Asselah T, Angus PW, et al. Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C (abstract LB-7). The Liver Meeting (2010) 61st Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 52. Boston, USA: Hepatology, 2010:223A.
27. Zeuzem S, Soriano V, Asselah T, et al. Virologic response to an interferon-free regimen of BI201335 and BI207127 with and without ribavirin in treatment naive patients with chronic genotype 1 HCV infection: week 12 interim results of the SOUND-C2 study (abstract LB-15). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Fransisco, USA: Hepatology, 2011:1436A.
28. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-50.
29. Gane EJ, Stedman CA, Hyland RH, et al. Once daily PSI-7977 plus RBV: pegylated interfron-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 (abstract 34). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:377A.
30. Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141:2047-55; quiz e14.
31. Barnard RJ, Zeuzem S, Vierling JM, et al. Analysis of resistanceassociated amino acid variants (RAVS) in non-SVR patients enrolled in a retrospective long-term follow-up analysis of boceprevir phase 3 clinical studies (abstract 164). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Fransisco, USA: Hepatology, 2011:440A-1A.
32. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatmentemergent resistant variants in telaprevir phase 3 clinical trials (abstract 8). The International Liver Congress (2011) 46th Annual Meeting of the European Association for the Study of the Liver. Vol. 54. Berlin, Germany: Journal of Hepatology, 2011:S4.
33. Vierling JM, Ralston R, Lawitz E, et al. Long-term outcomes following combination treatment with boceprevir plus peg-intron/ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1; abstract 2016). The International Liver Congress (2010)-45th Annual Meeting of the European Association for the Study of the Liver. Vol. 52. Vienna, Austria: Journal of Hepatology, 2010:S470-S1.
34. Sarrazin C, Reesink HW, Zeuzem S, et al. Retreatment with telaprevir/PEG-IFN/RBV after a short exposure to telaprevir in phase 1 studies: interim results from a phase IIIB rollover trial (C219; abstract 35). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:377A-8A.
35. Le Pogam S, Seshaadri A, Ewing A, et al. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010; 202:1510-9.
36. Pockros P, Jensen D, Tsai N, et al. First SVR data with the nucleoside analogue polymerase inhibitor Mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial (abstract 1359). The International Liver Congress (2011) 46th Annual Meeting of the European Association for the Study of the Liver. Vol. 54. Berlin, Germany: Journal of Hepatology, 2011:S538.
37. Flisiak R, Pawlotsky JM, Crabbe R, et al. Once daily alisporivir (DEB025) plus PEGIFNALFA2A/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naive patients (abstract 4). The International Liver Congress (2011) 46th Annual Meeting of the European Association for the Study of the Liver. Vol. 54. Berlin, Germany: Journal of Hepatology, 2011:S2.
38. Garcia-Rivera J, Hernandez F, Baugh JM, Lin K, Gallay P. Analysis of the anti-HCV mechanisms of action of the cyclophilin inhibitor alisporivir (abstract 387). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:551A.
39. Li B, Snoeck J, Tang Y, et al. Alisporivir-a host-targeting antiviral, provides low viral breakthrough rate and high barrier to resistance in HCV genotype 1 treatment-naive patients in the phase IIB ESSENTIAL study (abstract 1350). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:997A-8A.
40. Pawlotskly JM, Flisiak R, Rasenack J, et al. Once daily alisporivir interferon (IFN)-free regimens achieve high rates of early HCV clearance in previously untreated patients with HCV genotype (G) 2 or 3 (abstract LB-11). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:1433A.
41. Korba B, Farrar KE, Yon C. Nitazoxanide exhibits synergy with HCV protease inhibitors and prevents the emergence of telaprevir-resistant HCV mutants in combination treatments in cell culture (abstract 377). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:546A.
42. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009; 136:856-62.
43. Grammatikos G, Susser S, Schwendy S, et al. Neither vitamin D levels nor genetic polymorphisms within the 25-, and the 1α? vitamin D hydroxylase are associated with viral clearance following interferonbased therapy in patients with genotype 1 chronic hepatitis C (abstract 1332). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:987A.
44. Matsumura T, Kato T, Tasak-Fujita M, et al. 25-Hydroxyvitamin D inhibits hepatitis C virus replication and production of the infectious viruses (abstract 379). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:547A.
45. Gal-Tanamy M, Bachmetov L, Ravid A, et al. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 2011; 54:1570-9.
46. Kondo C, Atsukawa M, Itokawa N, et al. Effect of fluvastatin-combined pegylated-interferon/ribavirin combination therapy on chronic hepatitis C (abstract 1335). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:989A.
47. Rao GA, Pandya PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 2011; 140:144-52.
48. Chojkier M, ElKhayat HR, Sabry D, Donohue MC, Buck M. Pioglitazone decreases hepatitis C viral load in overweight patients with genotype 4 infection in Egypt: a randomized pilot study (abstract LB-26). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:1443A.
49. Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010; 30:447-54.
50. Gordon SC, Chung RT, Curry MP, et al. Monoclonal antibody MBLHCV1 suppresses return of HCV following liver transplantation (abstract LB-12). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:1434A.
51. Furusyo N, Murata M, Ogawa E, et al. Selective estrogen receptor modulator enhances the efficacy of pegylated interferon alpha plus ribavirin treatment for menopausal women with chronic hepatitis C (abstract LB-27). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco, USA: Hepatology, 2011:1444A.
52. Chhatwal J, Ferrante S, Dasbach E, et al. Cost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype 1 who failed prior treatment with peginterferon/ribavirin (abstract 940). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco: Hepatology, 2011:801A.
53. Deniz B, Brogan A, Miller J, Talbird S, Thompson J. Projections using decision-analytic modeling of long-term clinical value of telaprevir for the treatment of HCV patients who had failed prior pegInterferon/ribavirin treatment (abstract 943). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco: Hepatology, 2011:802A-3A.
54. Ferrante S, Chhatwal J, Elbasha E, et al. Cost-effectiveness of boceprevir based regimens in previously untreated adult subjects with chronic hepatitis C genotype 1 (abstract 929). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco: Hepatology, 2011:795A-6A.
55. Gellad Z, Naggie S, Reed S, et al. The cost-effectiveness of a telaprevirinclusive regimen as initial therapy for genotype 1 hepatitis C infection in individuals with the CC IL-28B polymorphism (abstract 118). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Disease. Vol. 54. San Francisco: Hepatology, 2011:417A-8A.
56. Petry A, Fraser I, O'Mara E, et al. Safety and antiviral activity of MK-5172, a next generation HCV NS3/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients (abstract 346). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Disease. Vol. 54. San Francisco: Hepatology, 2011:531A.
57. Hayashi N, Nakamura K, Wright D, et al. Safety and efficacy of vaniprevir (MK-7009) in combination with peg-interferon alfa-2A (PEG-IFN)/ribavirin (RBV) in genotype 1 treatment experienced HIV-infected Japanese patients (abstract 1347). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco: Hepatology, 2011: 996A.
58. Lawitz E, Rodriguez-Torres M, Stoehr A, et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment (abstract LB-13). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco: Hepatology, 2011:1434A-5A.
59. Lalezari JP, Hazan L, Kankam M, et al. High rapid virologic response (RVR) with ACH-1625 daily dosing plus PEGIFN-ALPHA 2A/RBV in a 28-day phase 2A trial (abstract 1341). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco: Hepatology, 2011: 992A-3A.
60. Ludmerer S, Fandozzi C, Huang Q, et al. Discovery of MK-4882, a novel inhibitor of HCV NS5A with an attractive pre-clinical profile (abstract 347). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco: Hepatology, 2011:531A-2A.
61. Guedj J, Dahari H, Tafoya E, Smith PF, Perelson AS. High sustained virologic response (SVR 24) rates with response-guided danoprevir (DNV; RG7227) plus PEGIFN α-2A (40KD) and ribavirin (P/R) in treatment-naïve HCV genotype 1 (G1) patients: Results from the ATLAS study (abstract 80). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Vol. 54. San Francisco: Hepatology, 2011:399A.
62. Rodriguez-Torres M, Lawitz E, Hazan L, et al. Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7-days of oral therapy in naïve genotype 1 chronic HCV patients (abstract 354). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Diseases Vol. 54. San Francisco: Hepatology, 2011:535A.
63. Leempoels J, Reesink HW, Bourgeois S, et al. Human safety, pharmacokinetics and antiviral activity of TMC647055, a novel HCV nonnucleoside polymerase inhibitor (abstract 350). The Liver Meeting (2011) The 62nd Annual Meeting of the American Association for the Study of Liver Disease. Vol. 54. San Francisco: Hepatology, 2011:533A.